Long-Term Clinical Outcomes After Switching from Remicade(®) to Biosimilar CT-P13 in Inflammatory Bowel Disease

BACKGROUND: Limited data are available on long-term clinical outcomes regarding the switch from Remicade(®) to the infliximab biosimilar CT-P13 in inflammatory bowel disease (IBD) patients. AIMS: To investigate long-term efficacy, safety, pharmacokinetic profile, and immunogenicity. METHODS: We perf...

Descripción completa

Detalles Bibliográficos
Autores principales: Smits, Lisa J. T., Grelack, Anna, Derikx, Lauranne A. A. P., de Jong, Dirk J., van Esch, Aura A. J., Boshuizen, Ronald S., Drenth, Joost P. H., Hoentjen, Frank
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2017
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5649598/
https://www.ncbi.nlm.nih.gov/pubmed/28667429
http://dx.doi.org/10.1007/s10620-017-4661-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5649598/
https://www.ncbi.nlm.nih.gov/pubmed/28667429
http://dx.doi.org/10.1007/s10620-017-4661-4

Ejemplares similares